Skip to main content
Fig. 4 | AIDS Research and Therapy

Fig. 4

From: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Fig. 4

Changes from baseline in BMD over time (hip and lumbar spine) based on demographic characteristics. BMD bone mineral density, D/C/F/TAF darunavir/cobicistat/emtricitabine/tenofovir alafenamide, SE standard error. *Data are from the bone investigation substudy, which included 209 patients in the D/C/F/TAF arm and 108 patients in the control arm. The total number of substudy patients in each treatment arm for each subgroup is reported in the legends

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us